Share on LinkedInShare on LinkedIn

ARTICLE · 08 JULY 2015

Compulsory License For Astrazeneca's Diabetes Management Drug Saxagliptin?

Khaitan & Co.
Khaitan & Co.
Contributor
Khaitan & Co.

Khaitan & Co.

Founded in 1911, Khaitan & Co is a heritage law firm that has been a trusted adviser to leading...

View firm profile
Explore more from Khaitan & Co.

In a recent development, a compulsory license (CL) application has been filed for the patent covering AstraZeneca's diabetes management drug Saxagliptin.

IndiaIntellectual Property

In a recent development, a compulsory license (CL) application has been filed for the patent covering AstraZeneca's diabetes management drug Saxagliptin. The CL has been filed by Lee Pharma Limited (CL Applicant), a Hyderabad based pharmaceutical company engaged in the manufacture and supply of pharmaceutical products, pharmaceutical formulations, intermediates and active pharmaceutical ingredients.

Background

The drug, Saxagliptin, is protected and covered by Indian patent no 206543 (Patent) titled "A cyclopropyl-fused pyrrolidine-based compound", granted on 30 April 2007 to Bristol-Myers Squibb Company (BMS).  BMS assigned the ownership rights on the Patent to AstraZeneca AB on 3 April 2014. Saxagliptin is adipeptidyl peptidase-4 inhibitor,used to treat Type II Diabetes Mellitus by achieving glycemic controlwithout accompanying weight gain.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from